{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:47:29Z","timestamp":1761562049835,"version":"3.41.0"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,1,24]],"date-time":"2016-01-24T00:00:00Z","timestamp":1453593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Paritaprevir (administered with low\u2010dose ritonavir), ombitasvir, and dasabuvir are direct\u2010acting antiviral agents administered as combination regimens for the treatment of chronic hepatitis C virus infection. Drug\u2013drug interactions between 2D (ombitasvir\/paritaprevir\/ritonavir) or 3D (ombitasvir\/paritaprevir\/ritonavir and dasabuvir) regimens and omeprazole, a CYP2C19 substrate and acid\u2010reducing agent, were evaluated in 24 healthy volunteers. Subjects received omeprazole (40 mg once daily) on day 1 and days 20\u201324 and the 2D or 3D regimen (ombitasvir\/paritaprevir\/ritonavir 25\/150\/100 mg once daily \u00b1 dasabuvir 250 mg twice daily) on days 6\u201324. Compared with omeprazole alone, coadministration with the 2D or 3D regimen decreased omeprazole geometric mean C<jats:sub>max<\/jats:sub>and AUC<jats:sub>t<\/jats:sub>values by 40% to 50%. Ombitasvir, dasabuvir, and ritonavir mean exposures showed &lt;10% change, and paritaprevir mean exposures showed &lt;20% change when the 2D or 3D regimen was administered with omeprazole compared with administration without omeprazole. Although no a priori dose adjustment is needed, a higher omeprazole dose should be considered if clinically indicated when coadministered with the 2D or 3D regimen. No dose adjustment is required for the 2D or 3D regimen when administered with omeprazole, other acid\u2010reducing agents, or CYP2C19 inhibitors.<\/jats:p>","DOI":"10.1002\/cpdd.246","type":"journal-article","created":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T16:53:11Z","timestamp":1449593591000},"page":"269-277","source":"Crossref","is-referenced-by-count":22,"title":["Drug\u2013Drug Interaction of Omeprazole With the HCV Direct\u2010Acting Antiviral Agents Paritaprevir\/Ritonavir and Ombitasvir With and Without Dasabuvir"],"prefix":"10.1002","volume":"5","author":[{"given":"Akshanth R.","family":"Polepally","sequence":"first","affiliation":[{"name":"AbbVie Inc North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Hu","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Podsadecki","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid M.","family":"Awni","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev M.","family":"Menon","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2014.09.008"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27705"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60159-3"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.10.027"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.07.011"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2013.07.008"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.016089"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000219774.20174.64"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K615"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000152"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00158a001"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198632010-00002"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/290159a0"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.24.4.270"},{"volume-title":"delayed\u2010release capsules [US prescribing information]","year":"2014","author":"Prilosec (omeprazole)","key":"e_1_2_9_21_1"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04310.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.040394"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.041293"},{"key":"e_1_2_9_25_1","unstructured":"United States Food and Drug Administration. Guidance for Industry. Drug interaction studies\u2212study design data analysis implications for dosing and labeling recommendations.2012.http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf. Accessed September 4 2015."},{"key":"e_1_2_9_26_1","unstructured":"European Medicines Agency.Guideline on the investigation of drug interactions.CPMP\/EWP\/560\/95\/Rev. 1 Corr.2012.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf. Accessed September 4 2015."},{"key":"e_1_2_9_27_1","unstructured":"GermanP YangJ WestS HanL SajwaniK MathiasA.Effect of food and acid reducing agents on the relative bioavailability and pharmacokinetics of ledipasvir\/sofosbuvir fixed dose combination tablet. 15th International Workshop on Clinical Pharmacology of HIV 7 Hepatitis Therapy 19\u201321 May 2014 Washington DC. Abstract P_15. 2014."},{"key":"e_1_2_9_28_1","unstructured":"EleyT GardinerD PerssonA et\u00a0al.Evaluation of Drug Interaction Potential of the HCV Protease Inhibitor BMS\u2010650032 at 200mg Twice Daily (BID) in Metabolic Cocktail and P\u2010glycoprotein (P\u2010GP) Probe Studies in Healthy Volunteers. 62nd Annual Meeting of the American Association for the Study of Liver Diseases. Nov 4\u20138 2011. San Francisco CA.http:\/\/www.natap.org\/2011\/AASLD\/AASLD_79.htm."},{"issue":"1","key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"S416","DOI":"10.1016\/S0168-8278(10)61077-X","article-title":"Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers","volume":"52","author":"Sekar V","year":"2010","journal-title":"J Hepatol"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","unstructured":"BadriPS DuttaS WangH et\u00a0al.Drug interactions with the direct\u2010acting antiviral combination of ombitasvir and paritaprevir\u2010ritonavir.Antimicrob Agents Chemother.2015;60(1):105\u2013114. DOI10.1128\/AAC.01778\u201015.","DOI":"10.1128\/AAC.01778-15"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.01.026"},{"key":"e_1_2_9_32_1","unstructured":"BowDAJ LiuJ KavetskaiaO et\u00a0al.A mechanistic non\u2010clinical assessment of drug\u2010drug interactions (metabolism and transporters) with the hepatitis C virus (HCV) regimen: ABT\u2010450\/r ombitasvir and dasabuvir. Poster presented at: 2014 American Association for the Study of Liver Diseases\/European Association for the Study of the Liver Special Conference on Hepatitis C; September 12\u201313 2014; New York NY."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010015\u20100317\u20108"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3565(25)12840-1","article-title":"Cytochrome P450\u2010mediated metabolism of the HIV\u20101 protease inhibitor ritonavir (ABT\u2010538) in human liver microsomes","volume":"277","author":"Kumar GN","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(85)80133-5"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.246","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T17:49:52Z","timestamp":1748713792000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,24]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1002\/cpdd.246"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.246","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"type":"print","value":"2160-763X"},{"type":"electronic","value":"2160-7648"}],"subject":[],"published":{"date-parts":[[2016,1,24]]}}}